![](/imgs/covers/cn_cover.jpg)
|
Indian Journal of Cancer
Medknow Publications on behalf of Indian Cancer Society
ISSN: 0019-509X EISSN: 0019-509X
Vol. 48, No. 4, 2011, pp. 438-445
|
Bioline Code: cn11122
Full paper language: English
Document type: Review Article
Document available free of charge
|
|
Indian Journal of Cancer, Vol. 48, No. 4, 2011, pp. 438-445
en |
Nilotinib as first-line therapy for chronic myeloid leukemia
Vaid, A
Abstract
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
Keywords
Tyrosine kinase inhibitor, response, safety, overcoming resistance
|
|
© Copyright 2011 - Indian Journal of Cancer Alternative site location: http://www.indianjcancer.com/
|
|